New Drug For T315I Mutation Which Causes Gleevec Resistance
Posted by rob on July 27, 2005 under Uncategorized | 
Be the First to Comment
Ambit Biosciences has announced the discovery of a new drug that may work on the T315I
mutation which causes Gleevec resistance in CML patients. This may become another
important new drug in the CML pipeline.
